Last updated: 2026-09-06 23:54:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
CytomX Therapeutics, Inc. (CTMX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.72, with a market capitalization of $810.59M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.90 to $8.21. This page covers its latest market performance, valuation, price trends and company information.
$810.59M | |
$3.64 | |
$35.00 | |
$0.40 | |
$3.68 | |
2.03M | |
-- | |
-- | |
$8.21 | |
$1.90 | |
-- | |
-- |
CytomX Therapeutics, Inc. (CTMX) last closed at $3.68 as of 2026-09-04 23:57:00, unchanged from the previous close of $3.68.
During the latest regular trading session, CTMX traded between $0.40 and $35.00, with a volume of 2.03M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, CytomX Therapeutics, Inc. (CTMX) moved from $3.20 to $3.72, representing a gain of 16.09% ($0.51).
The stock traded between $3.53 and $3.72 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 3.90 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 28.8%
CTMX is currently trading at $3.72, placing it 28.8% of the way from its 52-week low of $1.90 to its 52-week high of $8.21. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 69 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of CytomX Therapeutics, Inc. (CTMX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.